Navigation Links
Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
Date:11/1/2007

%), thrombocytopenia and appetite decreased (including anorexia) (each 36%), pyrexia (34%), vomiting (33%), and anemia (29%). Twenty percent (20%) of patients experienced at least 1 episode of >/= Grade 4 toxicity, most commonly thrombocytopenia (5%) and neutropenia (3%). A total of 50% of patients experienced serious adverse events (SAEs) during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%). Adverse events thought by the investigator to be drug-related and leading to discontinuation occurred in 22% of patients. The reasons for discontinuation included peripheral neuropathy (8%), asthenic conditions (3%) and thrombocytopenia and diarrhea (each 2%). In total, 2% of the patients died and the cause of death was considered by the investigator to be possibly related to study drug: including reports of cardiac arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis. This integrated analysis does not include the phase 3, VELCADE plus DOXIL study.

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Millennium's website is http://www.millennium.com.

This pre
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... SAN ANTONIO , 23 de julio de ... ADBI (ADBI o la Compañía) ha anunciado hoy ... Akron (ABIA o el Instituto), ... de ADBI, un dispositivo de terapia de señal ...   El Instituto, que tiene una ...
(Date:7/23/2014)... 23, 2014 /PRNewswire/ - BioAmber Inc. (NYSE: ... sustainable chemicals, today announced that the underwriters of its ... to purchase an additional 420,000 shares of common ... per share, less underwriting discounts and commissions, in ... of 2,800,000 shares of common stock, bringing the ...
(Date:7/23/2014)... 23, 2014  Sofinnova Ventures, a Menlo ... closing of Sofinnova Venture Partners IX, L.P. at the ... the initial fund target of $425 million. ... companies. Consistent with recent funds, SVP IX will provide ... programs, along with select investments in earlier stage opportunities. ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 a2z Inc. ... ChirpE Mobile App, AACC Pathfinder, in its 2014 ... AACC’s annual meeting is planned for July 29-31, 2014 ... place to be to connect with global leaders in ... management, and other areas of breaking science in laboratory ...
Breaking Biology Technology:ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3Sofinnova Raises $500 Million Biotech Venture Fund 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 3
... sales of $84.0 million, a 7% increase over last year,s first , ... year-over-year , - Record pre-tax income of $15.4 million , - ... , first quarter , - New products ... , - Improvements in gross margin continue to demonstrate the strong ...
... 4 SenesTech, Inc. scientists, Drs. Loretta Mayer, ... attend the Third International Workshop on Fertility Control ... they presented SenesTech,s latest developments in humane animal ... organized by the governments of Australia, the United ...
... Micell Technologies announced today that David E. Kandzari, ... DES System" during the Cardiovascular Research Technologies (CRT) ... MiStent(TM), a Drug-Eluting Stent (DES) in pre-clinical studies, ... potential benefits of the drug during the healing ...
Cached Biology Technology:Martek Announces First Quarter 2009 Financial Results 2Martek Announces First Quarter 2009 Financial Results 3Martek Announces First Quarter 2009 Financial Results 4Martek Announces First Quarter 2009 Financial Results 5Martek Announces First Quarter 2009 Financial Results 6Martek Announces First Quarter 2009 Financial Results 7Martek Announces First Quarter 2009 Financial Results 8Martek Announces First Quarter 2009 Financial Results 9Martek Announces First Quarter 2009 Financial Results 10SenesTech Scientists Attend International Workshop on Fertility in New Zealand 2Micell Technologies' Rapid Absorption Polymer DES System to be Presented at CRT 2009 2
(Date:7/23/2014)... or neglected early in life are at risk ... In a new study, scientists have found that ... has implications for children,s long-term development. Previous studies ... and genetics interacted with that child,s experiences in ... In the new study, researchers were able to ...
(Date:7/23/2014)... Mass. Honey bees, especially the young, are highly ... work together to maintain temperatures within a narrow range. ... biologist at Tufts University,s School of Arts and Sciences, ... excess heat within a hive in process similar to ... blood vessels and skin. , "This study shows ...
(Date:7/23/2014)... super strength, but it also holds the promise of ... ability to convert sunlight into a clean, efficient alternative ... international group using spinach to study the proteins involved ... sun,s energy into carbohydrates used to power cellular processes. ... most efficient system ever built, capable of converting the ...
Breaking Biology News(10 mins):Stress tied to change in children's gene expression related to emotion regulation, physical health 2Stress tied to change in children's gene expression related to emotion regulation, physical health 3How honey bees stay cool 2Spinach could lead to alternative energy more powerful than Popeye 2
... the standard biological model of animal cell communication, UCSF ... the ability to transmit and receive biological signals by ... distance. The mechanism is similar to the way ... understanding that non-neuronal cells "basically spit out signaling proteins ...
... not the only organ in your body that can sense cigarette ... Louis and the University of Iowa have showed that your lungs ... nose, which are located in the membranes of nerve cells, the ... Instead of sending nerve impulses to your brain that allow it ...
... early indication of lay opinions on research with induced ... from skin or other tissues, a new study by ... ethical concerns, patients give the research "broad endorsement". ... of participating in iPSC research even if personal benefit ...
Cached Biology News:Animal cells can communicate by reaching out and touching, UCSF team discovers 2Animal cells can communicate by reaching out and touching, UCSF team discovers 3Odor receptors discovered in lungs 2Odor receptors discovered in lungs 3Odor receptors discovered in lungs 4Study finds patients give 'broad endorsement' to stem cell research 2Study finds patients give 'broad endorsement' to stem cell research 3
Rat monoclonal [HK5.3] to B7 RP1 (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
... with the HECT protein, E6-AP ... Evidence suggests that this E2 ... degradation of non-""N-end rule"" protein ... -acetylated proteins as well as ...
NANS Immunogen: NANS (NP_061819, 260 a.a. ~ 360 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
ANTI-RAT ADHESION MARKERS, CDs, CYTOKINES, ETC Rat ICAM PE - Mouse IgG1...
Biology Products: